Abstract
Ayurvedic medicines, though widely marketed across Western countries as food supplements, herbal remedies, or traditional health products, are not recognized as licensed pharmaceuticals requiring efficacy disclosure. Their legal entry is facilitated through frameworks such as the U.S. Dietary Supplement Health and Education Act (DSHEA), the EU Traditional Herbal Medicinal Products Directive (THMPD), Canada’s Natural Health Products Regulations, and Australia’s complementary medicine listing system.
Despite bypassing pre-market drug approval, these products remain under post-market pharmacovigilance surveillance. Healthcare providers are obliged to document usage and report adverse reactions to national pharmacovigilance agencies, which collate, analyze, and establish causality using WHO-UMC criteria.
Major Adverse Reactions Associated With Ayurvedic Medicines
Scientific literature has documented major adverse reactions to Ayurvedic supplements, including hepatotoxicity (Tinospora cordifolia, Ashwagandha, turmeric, and Psoralea corylifolia), hypersensitivity reactions, and heavy-metal poisoning (lead, mercury, and arsenic).
Case reports from the United States, the United Kingdom, and India substantiate these risks, with outcomes ranging from acute liver failure to Cushing’s syndrome due to steroid adulteration.
| Reported Risk | Examples | Potential Outcome |
|---|---|---|
| Hepatotoxicity | Tinospora cordifolia, Ashwagandha, Turmeric, Psoralea corylifolia | Liver injury and acute liver failure |
| Hypersensitivity reactions | Various herbal preparations | Allergic and other hypersensitivity reactions |
| Heavy-metal poisoning | Lead, mercury, arsenic | Potential systemic toxicity |
| Steroid adulteration | Adulterated Ayurvedic products | Cushing’s syndrome and related complications |
Indian Regulatory Response and Pharmacovigilance
Indian statutory bodies—including the Ministry of AYUSH, CDSCO, ICMR, and NCISM—have acknowledged these concerns, establishing the Ayush Pharmacovigilance Program of India (APvPI) and issuing guidelines for adverse drug reaction reporting.
This deliberation highlights the tension between traditional use and modern regulatory safeguards, underscoring the need for harmonized global vigilance, transparent labeling, and evidence-based integration of Ayurvedic medicines into healthcare systems.
Global Use And Regulatory Classification Of Ayurvedic Medicines
Ayurvedic medicines enjoy wide popularity and are extensively used across many countries. Although they are not formally included in national pharmacopeias and lack approval from drug controllers, they are nevertheless marketed under categories that do not require such approval—typically as herbal preparations, food supplements, or traditional home remedies.
Classification in Western Jurisdictions
In Western jurisdictions, these products are generally classified as herbal supplements, dietary supplements, or traditional remedies, rather than licensed pharmaceutical drugs.
This classification enables them to bypass stringent drug approval procedures while still obligating manufacturers to comply with consumer safety regulations, quality standards, and labeling requirements.
Key Regulatory Frameworks
| Jurisdiction | Regulatory Framework Mentioned | General Product Category |
|---|---|---|
| United States | Dietary Supplement Health and Education Act (DSHEA) | Dietary supplements |
| European Union | Traditional Herbal Medicinal Products Directive (THMPD) | Traditional herbal medicinal products |
| Canada | Natural Health Products Regulations | Natural health products |
| Australia | Complementary medicine listing system | Complementary medicines |
Key Regulatory and Safety Issues
- Classification: Ayurvedic products may be regulated differently from licensed pharmaceutical drugs.
- Pre-market approval: Certain regulatory frameworks do not require the same level of pre-market drug approval for these products.
- Post-market surveillance: Adverse reactions may remain subject to pharmacovigilance and safety monitoring.
- Quality and labeling: Manufacturers must comply with applicable consumer safety, quality, and labeling requirements.
- Adverse reactions: Scientific literature has reported hepatotoxicity, hypersensitivity reactions, heavy-metal poisoning, and risks associated with adulteration.
- Global harmonization: Greater consistency in safety monitoring and transparent labeling can support safer use.
Ayurvedic Medicine Regulation in Western Countries
United States
Legal Basis:
Governed by the Dietary Supplement Health and Education Act (DSHEA, 1994).
Ayurvedic products are treated as dietary supplements, not drugs.
Requirements:
- Must be manufactured under Good Manufacturing Practices (GMP).
- Labels must carry disclaimers: “This product is not intended to diagnose, treat, cure, or prevent any disease.”
- No prior FDA approval required, but FDA can act if products are unsafe or make false claims.
Implication: Companies market Ayurvedic remedies as “natural supplements” rather than medicines.
European Union
Legal Basis:
Governed by the EU Directive 2004/24/EC on Traditional Herbal Medicinal Products (THMPD).
Requirements:
- Products can be registered under a simplified scheme if they show at least 30 years of traditional use (15 years in the EU).
- Must meet safety, quality, and labeling standards.
- Cannot claim therapeutic benefits beyond “traditional use.”
Implication: Ayurvedic medicines are often sold as herbal remedies or food supplements, avoiding full pharmaceutical trials.
United Kingdom (Post-Brexit)
Legal Basis:
Follows a similar framework to the EU THMPD but is regulated by the Medicines and Healthcare Products Regulatory Agency (MHRA).
Requirements:
- Ayurvedic products can be registered as Traditional Herbal Remedies (THR).
- Must meet safety and quality standards, but efficacy is judged only on traditional use.
Implication: Marketed as “herbal remedies” with restricted claims.
Canada
Legal Basis:
Regulated under the Natural Health Products Regulations (NHPR).
Requirements:
- Must obtain a Natural Product Number (NPN) before sale.
- Safety and quality must be demonstrated, but efficacy can rely on traditional evidence.
Implication: Ayurvedic medicines are sold as Natural Health Products (NHPs).
Australia
Legal Basis:
Regulated by the Therapeutic Goods Administration (TGA).
Requirements:
- Listed medicines (low-risk) can include Ayurvedic products.
- Must comply with labeling and safety standards.
Implication: Marketed as complementary medicines, not mainstream pharmaceuticals.
Key Risks & Trade-offs
- Safety Concerns: Heavy metals (lead, mercury, and arsenic) are sometimes found in Ayurvedic formulations.
- Marketing Loophole: By classifying as supplements, companies avoid rigorous drug trials.
- Consumer Protection: Regulators can intervene only after adverse events or misleading claims.
In summary: Ayurvedic medicines in Western countries are marketed legally under dietary supplement, herbal remedy, or natural health product laws, not as approved pharmaceuticals. This allows wide availability but limits therapeutic claims and places responsibility on manufacturers for safety and labeling.
Post-Market Surveillance Of Ayurvedic Products
Even though they are not marked as drugs, requiring disclosure of their efficacy, they are under post-market surveillance for their ill effects on the consumers’ health. Health care units are obliged to document their use in the patient and report any adverse effect noted to the Pharmacovigilance Agency. The agency collects, collates, and analyzes these adverse reactions and works out their associations, correlations, and finally causal relationships.
Even though Ayurvedic and other herbal preparations are marketed as supplements rather than drugs, they are still subject to post-market surveillance systems in Western countries. Regulators recognize that “natural” does not mean “risk-free,” so adverse event monitoring is mandatory.
Post-Market Surveillance Framework
1. United States
System: FDA’s MedWatch program and the Dietary Supplement Adverse Event Reporting System (CAERS).
Obligation:
- Health professionals and consumers can report adverse events.
- Manufacturers are legally required to report serious adverse events to the FDA within 15 days.
Analysis: FDA collates reports, looks for patterns, and can issue warnings, recalls, or bans.
2. European Union
System: EudraVigilance (European Medicines Agency).
Obligation:
- Healthcare providers must document suspected adverse reactions, even for herbal/traditional remedies.
- National pharmacovigilance centers collect and forward data to EMA.
Analysis: Reports are pooled, associations are tested, and causality is assessed using standardized methods (e.g., WHO-UMC causality categories).
3. United Kingdom
System: Yellow Card Scheme (MHRA).
Obligation:
- Doctors, pharmacists, nurses, and patients can report suspected adverse reactions to herbal or Ayurvedic products.
Analysis: MHRA investigates signals, correlates with product batches, and can restrict or withdraw unsafe remedies.
4. Canada
System: Canada Vigilance Program.
Obligation:
- Healthcare institutions must report adverse reactions to Natural Health Products (NHPs).
Analysis: Health Canada evaluates causality and can suspend or revoke product licenses (NPN).
5. Australia
System: Adverse Event Management System (AEMS) under the TGA.
Obligation:
- Hospitals and practitioners report adverse events linked to complementary medicines.
Analysis: TGA applies causality assessment and can reclassify or delist products.
How Causality Is Established
Pharmacovigilance agencies follow a structured process:
- Collection: Adverse event reports from hospitals, clinics, consumers, and manufacturers.
- Collation: Data pooled into national/international databases.
- Association: Initial statistical link between product and adverse event.
- Correlation: Strength and consistency of relationship across cases.
- Causation: Confirmed through:
- Temporal relationship (did the event follow product use?).
- Dechallenge/rechallenge (did symptoms resolve when stopped, recur when restarted?).
- Biological plausibility (known toxic constituents, e.g., heavy metals).
- Exclusion of confounders (other drugs, comorbidities).
Substantiation
- WHO Guidelines on Safety Monitoring of Herbal Medicines (2004) explicitly require pharmacovigilance for traditional remedies.
- EU Directive 2004/24/EC mandates adverse reaction reporting for registered herbal medicines.
- FDA DSHEA (1994) requires manufacturers to report serious adverse events.
- The MHRA Yellow Card Scheme includes herbal and Ayurvedic products.
In essence: Even though Ayurvedic medicines are marketed as supplements, they are not exempt from pharmacovigilance. Healthcare units must document usage and adverse effects, regulators collate data, and causality is carefully worked out before regulatory action. This ensures consumer safety while respecting traditional use.
Adverse Reactions Reported in Scientific and Medical Journals
These adverse reactions are reported in scientific and medical journals. Details of major such reported adverse reactions to Ayurvedic preparations sold as food supplements, herbal products, or traditional remedies. Review articles in PubMed.
Several major adverse reactions to Ayurvedic preparations have been documented in peer-reviewed journals, especially when marketed as food supplements or herbal remedies. The most serious include hepatotoxicity, hypersensitivity reactions, and heavy-metal poisoning. Multiple PubMed reviews consolidate these findings, highlighting the global pharmacovigilance concern.
Key Review Articles (PubMed)
| Review | Focus | Major Findings |
|---|---|---|
| Signals of Adverse Reactions to Herbal Medicines (Drug Safety, 2025) | Scoping review of global pharmacovigilance data | Identified signals of liver injury, renal toxicity, hypersensitivity, and heavy-metal poisoning linked to herbal medicines, including Ayurvedic preparations. |
| Immediate Hypersensitivity to Herbal Medicine (Curr Opin Allergy Clin Immunol, 2026) | Review of allergic reactions | Documented IgE-mediated and non-IgE-mediated hypersensitivity to herbal products; clinical manifestations include urticaria, asthma, and anaphylaxis. |
| Hepatotoxicity of Herbs in Indian Systems (Medicine, 2024) | Narrative review of liver injury | Highlighted hepatotoxicity from Tinospora cordifolia (Giloy), Ashwagandha, turmeric, Psoralea corylifolia (Bakuchi), and others. Reported cases of acute liver failure and chronic liver dysfunction. |
Documented Adverse Reactions
1. Hepatotoxicity
- Giloy (Tinospora cordifolia): Linked to autoimmune hepatitis and acute liver failure.
- Ashwagandha (Withania somnifera): Cases of cholestatic hepatitis.
- Turmeric (Curcuma longa): Rare but reported hepatocellular injury.
- Bakuchi (Psoralea corylifolia): Associated with fulminant hepatic failure.
2. Hypersensitivity & Allergy
Immediate hypersensitivity reactions (IHRs):
- Cutaneous: urticaria, angioedema.
- Respiratory: bronchospasm, asthma.
- Systemic: anaphylaxis.
Mechanisms: IgE-mediated and non-IgE pathways triggered by bioactive constituents or contaminants.
3. Heavy Metal Toxicity
- Lead, mercury, and arsenic contamination in Rasa Shastra preparations.
- Reported outcomes: neurotoxicity, nephropathy, anemia, and developmental delay in infants.
- Case reports in the US and UK have linked Ayurvedic supplements to severe lead poisoning.
4. Other Toxicities
- Nephrotoxicity: Linked to herbal diuretics and adulterated formulations.
- Cardiotoxicity: Rare reports of arrhythmias from stimulant herbs.
- Reproductive toxicity: Abortifacient effects of neem and guggulu in high doses.
Evidence From Journals
- Case reports and series in Medicine (Baltimore), Drug Safety, and Clinical Toxicology detail individual adverse events.
- Systematic reviews emphasize the need for stronger pharmacovigilance and regulatory oversight.
- WHO guidelines (2004) recommend integrating herbal medicine surveillance into national pharmacovigilance systems.
Takeaway
- Ayurvedic supplements are not risk-free. Documented adverse reactions include liver injury, hypersensitivity, and heavy-metal poisoning.
- Healthcare providers are obliged to report adverse events to pharmacovigilance agencies, which analyze causality.
- PubMed reviews substantiate these risks, making it clear that global monitoring is essential for patient safety.
Country-Wise Summary Of Published Case Reports
Country-wise summary of published case reports (e.g., US, UK, India) that specifically link Ayurvedic supplements to adverse outcomes:
Ayurvedic supplements have been linked to serious adverse outcomes across multiple countries, with case reports documenting liver injury, heavy-metal poisoning, hypersensitivity, and adulteration with steroids or pharmaceuticals. These reports are published in peer-reviewed journals and form part of pharmacovigilance databases internationally.
Country-Wise Case Report Summary
United States
- Lead Poisoning Cases: Several reports of women and children developing severe anemia, neurotoxicity, and developmental delay after consuming Ayurvedic supplements imported from India.
- FDA MedWatch Reports: Documented blood lead levels >60 µg/dL in pregnant women linked to Ayurvedic powders.
- Adulteration Cases: Supplements found to contain undeclared steroids and sildenafil analogs, leading to metabolic and cardiovascular complications.
United Kingdom
- Yellow Card Scheme Reports: Cases of hepatotoxicity and hypersensitivity reactions from Ayurvedic herbal tablets.
- Oxford University Case Series:
- A 35-year-old woman with hepatitis worsened after taking Ayurvedic powder and Swarnabhasma (gold salt), developing nephrotic syndrome.
- A 57-year-old man developed side effects from reserpine-containing Ayurvedic medicine (withdrawn in allopathy for toxicity).
- A 47-year-old woman developed Cushingoid features after 2 years of steroid-adulterated Ayurvedic tablets.
India
- BMC Complementary Medicine Case Series: Multiple reports of Ayurvedic medication-induced liver injury, including fulminant hepatic failure from Psoralea corylifolia (Bakuchi) and autoimmune hepatitis from Tinospora cordifolia (Giloy).
- National Pharmacovigilance Reports: Highlight adulteration with corticosteroids, leading to long-term metabolic complications.
- Heavy-Metal Contamination: Documented cases of mercury nephropathy and arsenic toxicity in rural populations consuming traditional powders.
Major Adverse Outcomes Documented
| Adverse Outcome | Examples / Associated Substances |
|---|---|
| Hepatotoxicity | Giloy, Ashwagandha, Turmeric, and Bakuchi. |
| Heavy-Metal Poisoning | Lead, mercury, and arsenic → anemia, renal failure, and neurotoxicity. |
| Steroid Adulteration | Cushing’s syndrome, diabetes, and osteoporosis. |
| Hypersensitivity | Urticaria, asthma, and anaphylaxis. |
| Reproductive Toxicity | Abortifacient effects of neem and guggulu in high doses. |
Takeaway
- The US, UK, and India have published peer-reviewed case reports linking Ayurvedic supplements to serious adverse events.
- These reports emphasize the need for pharmacovigilance, mandatory reporting, and stricter regulation of Ayurvedic nutraceuticals marketed as food supplements or herbal remedies.
- Healthcare providers must document and report adverse reactions, as they are critical for causality assessment and regulatory action.
Has the National Medical Council, Drugs Controller of India, the Indian Council of Medical Research, or other health care regulatory authorities, or the National Commission of the Indian System of Medicines, the concerned statutory bodies, taken note of these reports and issued cautions, warnings, or guidelines?
Indian statutory bodies have formally recognized the risks of adverse reactions from Ayurvedic and other AYUSH medicines. The Ministry of AYUSH launched the Ayush Pharmacovigilance Program of India (APvPI), and agencies like CDSCO, ICMR, and the National Commission for Indian System of Medicine (NCISM) have issued frameworks, guidelines, and cautionary advisories to strengthen post-market surveillance.
Key Regulatory Actions in India
1. Ministry of AYUSH
- Established the Ayush Pharmacovigilance Program of India (APvPI) in collaboration with WHO recommendations.
- Created a national pharmacovigilance network with reporting centers at the All India Institute of Ayurveda (AIIA), CCRAS institutes, and medical colleges.
- Issued guidelines for reporting adverse drug reactions (ADRs) in Ayurveda, Siddha, Unani, and homeopathy.
- Mandated standardized ADR reporting forms and causality assessment using WHO-UMC criteria.
2. Central Drugs Standard Control Organization (CDSCO)
- Integrated ASU&H drugs (Ayurveda, Siddha, Unani, and homeopathy) into the National Pharmacovigilance Program.
- Surveillance includes objectionable/misleading advertisements and adulteration with corticosteroids or NSAIDs.
- Works jointly with AYUSH to ensure quality control and safety monitoring.
3. Indian Council of Medical Research (ICMR)
- Conducts clinical safety studies on herbal medicines.
- Publishes guidelines for toxicity evaluation of traditional formulations.
- Collaborates with AYUSH and CDSCO to build evidence-based safety databases.
4. National Commission for Indian System of Medicine (NCISM)
- Endorses pharmacovigilance training for Ayurvedic practitioners.
- Requires documentation of adverse events in teaching hospitals.
- Promotes integration of pharmacovigilance into curricula and practice standards.
Key Concerns Highlighted
- Misconception of Safety: “Natural” ≠ “safe.” Long-term use or improper combinations can cause harm.
- Heavy-Metal Contamination: Lead, mercury, and arsenic in Rasa Shastra formulations.
- Steroid Adulteration: Linked to Cushing’s syndrome and metabolic disorders.
- Drug Interactions: With allopathic medicines, increasing risk of toxicity.
Takeaway
- India has formally acknowledged adverse reactions to Ayurvedic medicines.
- The Ayush Pharmacovigilance Program of India (APvPI) is the central framework for monitoring, reporting, and analyzing ADRs.
- Healthcare institutions are obliged to report adverse events, and statutory bodies (AYUSH, CDSCO, ICMR, and NCISM) have issued guidelines, warnings, and training mandates to strengthen safety oversight.
Concluding Paragraph
Transparency in the marketing and monitoring of Ayurvedic medicines is not merely a regulatory obligation but a moral imperative. When products are sold as food supplements or traditional remedies, the public must be clearly informed of their limitations, potential risks, and the absence of formal drug approval. Equally, adverse reactions must be openly documented and shared across pharmacovigilance networks to build trust and safeguard health. By fostering public awareness campaigns, transparent labeling, and accessible reporting systems, regulators and healthcare institutions can bridge the gap between traditional use and modern safety standards. Only through openness and vigilance can Ayurvedic medicines retain their cultural value while ensuring patient safety in a globalized marketplace.
Written By: Dr. Shri Gopal Kabra – MBBS, LLB, MSc, MS (Anatomy), MS (Surgery)
Director of Clinical Services, Bhagwan Mahaveer Cancer Hospital, Jaipur-302017
Email: [email protected], Ph. no.: 8003516198
